The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).
- Investigator
- Sub Subramony
- Status
- Accepting Candidates
- Ages
- 16 Years - N/A
- Sexes
- All
Neuromuscular Medicine Specialist
My name is Sub Subramony, MD, and I am a board-certified neurologist and neuromuscular medicine specialist at the Norman Fixel Institute for Neurological Diseases at UF Health. I also serve as a professor in the University of Florida Department of Neurology with a joint appointment in pediatrics.
I received my medical degree from Delhi University in 1971 and completed my neurology residency in 1978 and my neuromuscular medicine fellowship in 1980 at the Cleveland Clinic.
Every day, I am inspired by the many patients and families I have cared for over the years. In clinic, I see patients with a variety of neuromuscular disorders and have a focus on inherited conditions, including Friedreich ataxia (FA), spinocerebellar ataxias, muscular dystrophies, Charcot-Marie-Tooth disease, myotonia congenita, myopathies and more, but I have extensive experience in all aspects of neuromuscular medicine. Little known secret: many of my patients nicknamed me Dr. Sam!
As many of these conditions are chronic and disabling conditions that often have no “approved” therapies, I aim to provide the best advice regarding ancillary care methods but also to bring meaningful research efforts to these patients.
While research is important, research divorced from patient care is not meaningful to clinical efforts. My research involves interventional and observational projects, including many first in-human trials for genetic neuromuscular diseases such as Friedreich ataxia, myotonic dystrophy, facioscapulohumeral dystrophy and spinocerebellar ataxias. My overall focus is to bring hope to patients living with these disorders and their families. I have been a key contributor, as a Southeastern hub, for many international collaborative efforts in FA, spinocerebellar ataxias (SCAs), myotonic dystrophy and facioscapulohumeral dystrophy (FSHD).
During my free time, I travel to New York City frequently to see my children and grandchildren and enjoy watching the young ones grow and play. When I’m in Gainesville, I enjoy hiking the Hawthorne trails, reading non-fiction books and listening to classical music. Over the last few years, I have become interested in listening to talks on population genetics; what an amazing field.
Please note: Some physicians and practices might not accept a specific insurance plan. Our list is also subject to change, and sometimes that change is not yet reflected in this list. Please contact the practice to confirm that your insurance is accepted. A representative will be happy to assist you.
See all insurancesThe purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment basivarsen (DYNE-101) for the treatment of myotonic dystrophy 1 (DM1).
The primary purpose of the study is to evaluate the safety and tolerability of multiple intravenous (IV) doses of DYNE-101 administered to participants with Myotonic Dystrophy Type 1 (DM1). The study consists of 4 periods: A Screening Period (up to…
In this study, researchers will learn more about omaveloxolone, also known as BIIB141 or SKYCLARYS®. Omaveloxolone is already approved for people with Friedreich's Ataxia (FA) who are 16 years of age or older. However, it is not yet available for…
— Dr. Sub SubramonyBring excellent multi and inter disciplinary care to patients and families with genetic disorders of the neuromuscular system including myotonic dystrophy and inherited ataxias and bring innovative translational research to such patients